Cellular Uptake Helping Large Drug Molecules Get Into the Body

This patent concerns improving the cellular uptake and absorption of drug molecules, helping large compounds cross biological barriers to reach the body. It comes from Axcess (UK) Ltd, a company associated with oral delivery technology for peptides and proteins.

The Problem

Some of the most valuable medicines are large molecules such as peptides and proteins, but their size is also their weakness. When swallowed, they struggle to cross the wall of the gastrointestinal tract into the bloodstream, so many can only be given by injection. The barrier is partly the tightly packed cells lining the gut and partly the molecules’ poor ability to pass through cell membranes. Chemically altering the drug to help it cross can change how it works or add safety concerns. The need is for a way to boost the uptake and absorption of these molecules across biological barriers without modifying the active drug itself.

What This Invention Does

The patent relates to enhancing the cellular uptake and absorption of active molecules, particularly larger compounds that ordinarily cross membranes poorly. Rather than altering the drug, the approach uses a formulation that improves how the active is taken up across the barrier, so more of it reaches the target. The IPC classifications point to a formulation containing an amino acid type component together with a therapeutic purpose. By combining the active with agents that promote its passage across cell membranes and the gut lining, the invention aims to raise the fraction of an orally delivered large molecule that is actually absorbed. The filing covers the composition and its use to improve uptake, offering a route toward giving by mouth some drugs that would otherwise require injection.

Key Features

• Better uptake. The invention improves how active molecules are taken up across cell membranes.
• No drug modification. Absorption is boosted through formulation rather than by chemically altering the active.
• Large molecule focus. It targets peptides, proteins, and other compounds that normally cross barriers poorly.
• Oral route. The approach supports delivery by mouth of drugs that might otherwise need injection.
• Composition and use. The filing covers both the formulation and its use to enhance absorption.

Who Is Behind It

The applicant is Axcess (UK) Ltd, a company connected to the Axcess oral delivery technology, which is designed to increase the absorption of peptides and proteins across the intestinal wall using established pharmaceutical ingredients. The named inventors are Roger R. C. New and Glen Travers. This filing is a divisional application from an earlier related Australian application.

Why It Matters

Turning an injectable medicine into a pill can transform how easily patients can take it, improving comfort and adherence for long-term conditions. Technology that raises the absorption of large molecules without changing the drug itself opens the door to oral versions of therapies that today require needles. Protecting the invention in Australia supports the company’s delivery technology in the region.

Related Concepts

• Peptide – a class of large molecule the technology helps deliver.
• Cell membrane – the barrier that active molecules must cross to be taken up.
• Gastrointestinal tract – the route through which oral drugs are absorbed.
• Bioavailability – the fraction of a dose that actually reaches circulation.
• Amino acid – a component type referenced in the formulation.

---

AU 2026201992 was published in the Australian Official Journal of Patents on 2 April 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.